Methods Of Treating Hepatic Encephalopathy Using Rifaximin

Rifaximin is utilized to treat hepatic encephalopathy (HE) and reduce the frequency of associated hospitalization visits. The method comprises the oral administration of rifaximin in tablet form at a daily dosage between 1000 mg and 1200 mg (specifically 1100–1200 mg, or 550 mg twice daily) for a duration of 12 months or longer. Rifaximin, a non-systemic, broad-spectrum antibiotic, inhibits bacterial RNA synthesis to reduce gut-derived nitrogenous toxins. Efficacy is measured by increased time to first HE-related hospitalization or spontaneous bacterial peritonitis, decreased blood ammonia concentrations, improved Conn scores, reduced asterixis grades, and improved quality of life (CLDQ and Epworth Sleepiness Scale scores). Rifaximin may be administered alone or in conjunction with other agents, such as lactulose.